VEGFA and gastric cancer: Herein, we summarize the pre-clinical evidence supporting the synergy of anti-VEGF and anti-PD-1/PD-L1 in metastatic GC/GEJC and review the results of ongoing clinical trials evaluating this regimen to demonstrate that this emerging combination treatment has promising potential to advance the treatment paradigm of metastatic GC/GEJC.